PBCay One RSC Ltd Makes New $96,000 Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

PBCay One RSC Ltd acquired a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,864 shares of the company’s stock, valued at approximately $96,000. Verve Therapeutics makes up 0.0% of PBCay One RSC Ltd’s portfolio, making the stock its 13th biggest holding.

A number of other institutional investors also recently modified their holdings of the stock. ARK Investment Management LLC grew its stake in Verve Therapeutics by 35.1% in the fourth quarter. ARK Investment Management LLC now owns 7,025,116 shares of the company’s stock valued at $97,930,000 after acquiring an additional 1,824,549 shares during the period. Federated Hermes Inc. increased its stake in Verve Therapeutics by 57.2% during the 4th quarter. Federated Hermes Inc. now owns 3,980,372 shares of the company’s stock valued at $55,486,000 after purchasing an additional 1,448,003 shares in the last quarter. Vanguard Group Inc. raised its holdings in Verve Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 4,832,968 shares of the company’s stock worth $64,085,000 after buying an additional 741,753 shares during the last quarter. FMR LLC raised its holdings in Verve Therapeutics by 8.8% during the third quarter. FMR LLC now owns 6,577,562 shares of the company’s stock worth $87,218,000 after buying an additional 531,182 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Verve Therapeutics by 11.7% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,397,604 shares of the company’s stock valued at $33,423,000 after buying an additional 250,361 shares in the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on VERV shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Verve Therapeutics in a research report on Thursday, May 9th. Stifel Nicolaus dropped their target price on Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $35.00 price target on shares of Verve Therapeutics in a report on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Verve Therapeutics Trading Down 3.2 %

Shares of Verve Therapeutics stock opened at $5.42 on Monday. The business’s fifty day simple moving average is $6.17 and its 200 day simple moving average is $10.64. Verve Therapeutics, Inc. has a 12 month low of $4.90 and a 12 month high of $21.42.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Wednesday, May 8th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.11. The company had revenue of $5.70 million for the quarter, compared to analysts’ expectations of $2.11 million. Verve Therapeutics had a negative return on equity of 37.35% and a negative net margin of 1,226.51%. The firm’s revenue was up 305.6% compared to the same quarter last year. On average, sell-side analysts predict that Verve Therapeutics, Inc. will post -2.73 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Andrew D. Ashe acquired 76,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $6.26 per share, with a total value of $475,760.00. Following the acquisition, the insider now owns 342,509 shares in the company, valued at approximately $2,144,106.34. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 19.30% of the stock is currently owned by insiders.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.